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Introduction
In addition to its nutrient absorption function, the intestinal mucosa has an important barrier function. The intestinal epithelium forms a physical and biochemical barrier that separates intraluminal solutes from the rest of the body (Groschwitz & Hogan, 2009; Turner, 2009) . This selective barrier is mainly regulated by the intercellular tight junctions of enterocytes (Cereijido, 1992) . Dysfunctional regulation of the tight junctional complex may allow increased epithelial permeation of antigens and endotoxins, increasing the risk of mucosal inflammation or ulceration. In addition, duodenal mucosal bicarbonate secretion plays a key role in epithelial protection against acid discharged from the stomach. This epithelial ion transport mechanism is impaired in patients with duodenal ulcer disease (Isenberg et al. 1987) . The alkaline secretion maintains the juxtamucosal surface at neutrality, thus protecting the epithelium from acid-induced ulcerations.
In recent years, the importance of epithelial nutrient chemosensing has become evident. It has been shown that chemical receptors present at the apical membrane of the intestinal epithelium play an important role as sensors and modulators of epithelial cell function (Feinle-Bisset et al. 2004 ). Short-chain fatty acids (SCFAs) are mainly derived from the anaerobic micro-organism metabolism of fibres and carbohydrates in the large intestine (Cummings & Macfarlane, 1991) . Short-chain fatty acids are formed in straight-or branched-chain conformations of volatile fatty acids one to six carbons in length (Bergman, 1990) . Although the greatest sources of SCFAs, such as acetate, propionate and butyrate, are found in the large intestine (Mortensen & Clausen, 1996; Topping & Clifton, 2001 ), significant amounts of SCFAs are also found in the proximal small intestine. Short-chain fatty acids in the upper alimentary tract are mainly derived from oral bacteria or food supplementation (Høverstad et al. 1984) . High dietary fibre intake has been linked with a number of health benefits, including possible prevention of type 2 diabetes, and a proposed mechanism is via SCFA signalling (Mudgil & Barak, 2013) . Approximately 90% of the SCFAs present in the intestinal lumen are absorbed, and a high intake of dietary fibre will generate a higher concentration of SCFAs in blood plasma. The major fraction of the absorbed SCFAs entering the portal circulation is used as a substrate for hepatic lipogenesis and cholesterol biosynthesis, but significant amounts of SCFAs reach the blood circulation. In humans, fasting blood plasma concentrations of acetate, propionate and butyrate are approximately 245, 13 and 2.1 μmol l −1 , respectively (Jakobsdottir et al. 2013) . In portal blood, the concentrations of acetate may reach as high as 300-450 μM (Cuche & Malbert, 1999) .
In the small intestinal segment, SCFAs are not only absorbed as nutrients; they may also influence many physiological functions of the gastrointestinal tract (GIT; Le Poul et al. 2003; Vinolo et al. 2011; Tolhurst et al. 2012) . Luminal SCFAs in the small intestine have previously been shown to affect gastric motor contractility. Ileal perfusion with SCFAs has been shown to reduce the amplitude and increase the frequency of antral contractions, probably via a reflex that involves direct contact of these SCFAs with free fatty acid (FFA) receptors in the terminal ileum (Cuche & Malbert, 1999) . In addition, SCFAs have been shown to increase mineral absorption, lipid metabolism, mucin production and the expression of antimicrobial peptides (Kles & Chang, 2006) . The co-localization of FFA receptor-2 (FFA2; SCFAs receptor) and peptide YY (PYY) in the intestinal epithelium also support an important role for SCFAs in the regulation of gastrointestinal functions (Karaki et al. 2006) .
Free fatty acid receptors present on the glucagon-like peptide (GLP)-secreting enteroendocrine L cells may play a significant role in nutrient chemosensing (Karaki et al. 2006) . Dysregulation of this signalling pathway may cause functional gut symptoms and pathogenesis of metabolic disorders (Feinle-Bisset et al. 2004 ). This was elucidated by the research groups of Akiba and Kaji. They showed that the rate of duodenal mucosal bicarbonate secretion increased with the activation of the SCFA receptors FFA2 and FFA3, which involves Na + -coupled monocarboxylate transporter-1 (SMCT1) and monocarboxylate transporters (MCTs; Akiba et al. 2015; Kaji et al. 2015) . However, the role of SCFAs in the regulation of duodenal barrier function has not been fully described.
The aim of this study was to investigate the role of SCFAs in the regulation of duodenal barrier function by elucidating the effects of acetate and propionate on duodenal paracellular permeability, mucosal bicarbonate transport, transepithelial net fluid flux and motility in anaesthetized rats in vivo. To mimic postprandial conditions, SCFAs were either perfused luminally through the duodenal segment or administered by an I.V. infusion. Our results clearly show that SCFAs can modulate duodenal barrier function and motility by mechanisms that may involve glucagon-like peptide-2 (GLP-2). It has been suggested that aberrant signalling or chemosensing in response to duodenal SCFAs could potentially induce dysregulation of the barrier function and motility in patients with functional dyspepsia or inflammatory bowel syndrome.
Methods

Ethical approval
All experiments were performed according to the 8th edition (2011) of the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health and approved by Uppsala Ethics Committee for Experiments with Animals (Permit number: C309/10). The authors understand and complied with all ethical principles that the journal upholds.
Chemicals and drugs
51 Chromium-labelled EDTA ( 51 Cr-EDTA) was purchased from Perkin Elmer Life Sciences (Boston, MA, USA). Bovine albumin (A2153), sodium chloride (NaCl), potassium chloride (KCl), the anaesthetic 5-ethyl-5-(1 -methyl-propyl)-2-thiobarbiturate (Inactin R ), sodium acetate (S8750) and sodium propionate (P1880) were purchased from Sigma-Aldrich (St Louis, MO, USA). Glucagon-like peptide-2 (catalogue no. 2259) was purchased from Tocris Bioscience (Bristol, UK). Parecoxib (Dynastat R ; Pfizer, NY, USA) was obtained from Apoteket AB (Uppsala, Sweden).
Animals
Forty-eight male Sprague-Dawley rats weighing 300-350 g were obtained from Taconic, Ejby, Denmark. The animals were maintained in standardized temperature and light conditions (12 h-12 h light-dark cycle; temperature, 21-22°C). The rats were acclimated in the Animal Department for at least 1 week before experiments and were caged in groups of two or more with access to tap water and chow (R36; Lantmännen, Kimstad, Sweden) ad libitum. The animals were fasted but had free access to tap water for 16 h (overnight) before the experiments. Experiments were started by anaesthetizing the animal close to 08.00 h with Inactin R 120 mg (kg body weight)
I.P. To minimize preoperative stress, anaesthesia was performed within the Animal Department by the person who had previously handled the animals. Then, the rat was immediately transported to the laboratory for the surgical procedure.
Surgical procedure
In the laboratory, the animals were tracheotomized with a tracheal tube to facilitate respiration, and the body temperature was maintained at 37-38°C throughout the experiments using a heating pad controlled by a rectal thermistor probe. The surgical and experimental procedures have been described previously (Hällgren et al. 1995; Sommansson et al. 2014b) . A brief summary and some modifications are described here. Two femoral arteries and a femoral vein were catheterized with PE-50 polyethylene catheters (Becton, Dickinson & Co., Franklin Lakes, NJ, USA). For continuous recordings of the systemic arterial blood pressure, one of the arterial catheters containing 20 IU ml −1 heparin isotonic saline was connected to a transducer operating a PowerLab system (AD Instruments, Hastings, UK). The other arterial catheter was used for obtaining blood samples. The venous catheter was used for drug injections and for the infusion of saline and 51 Cr-EDTA at a rate of 1.0 ml h −1 . A laparotomy was performed, and the common bile duct was catheterized with PE-10 polyethylene tubing close to its entrance into the duodenum (2-3 mm) to prevent pancreaticobiliary juice from entering the duodenum. Soft silicone tubing (Silastic R ; Dow Corning, 1 mm i.d.) was introduced into the mouth, pushed gently along the oesophagus, guided through the stomach and pylorus, and secured by ligatures 2-5 mm distal to the pylorus. PE-320 tubing was inserted into the duodenum approximately 2.5-3.5 cm distal to the pylorus and secured by ligatures. The proximal duodenal tubing was connected to a peristaltic pump (Gilson Minipuls 3; Villiers, Le Bel, France), and the segment was continuously perfused with a 154 mM sodium chloride solution (saline) at a rate of ß0.4 ml min −1 . To complete the surgery, the abdominal cavity was closed with sutures, and the wound was covered with plastic foil. Parecoxib I.V. injection 10 mg kg −1 was given 30 min after completion of the surgery to reverse the surgery-induced paralysis of the intestine (Sababi & Nylander, 1994; Nylander et al. 2003; . After surgery, ß60 min was allowed for the cardiovascular, respiratory and intestinal function to stabilize before the experiments were commenced.
Measurement of duodenal mucosal permeability
After the completion of the surgery, 51 Cr-EDTA was administered as an I.V. bolus of ß75 μCi followed by a continuous infusion at a rate of ß50 μCi h −1 . The radioactive isotope was diluted in saline and infused at a rate of 1.0 ml h −1 . One hour was permitted for the tissue equilibration of the 51 Cr-EDTA. Two blood samples (ß0.2 ml each) were collected; the first was collected 10 min before starting the experiment and the second after ending the experiment. The blood volume loss of the first blood sample was compensated by an injection of 0.2 ml of 7% bovine albumin solution. After centrifugation, 50 μl of the plasma was removed for measurements of radioactivity.
The duodenal segment was perfused with saline at a rate of 0.4 ml min −1 , and the perfusate was collected at 10 min intervals. The luminal perfusate and blood plasma were analysed for 51 Cr activity using a γ counter (1282 Compugamma CS; Pharmacia, Uppsala, Sweden). A linear regression analysis of the plasma samples was made to obtain a corresponding plasma value for each perfusate sample. The clearance of 51 Cr-EDTA from the blood to the lumen was calculated as described previously (Nylander et al. 1989; Sommansson et al. 2013 ) and expressed as millilitres per minute per 100 grams.
Measurement of duodenal wall contractions
Measurement of intraluminal pressure was used to assess the duodenal wall contractions. The inlet perfusion tubing was connected, via a T-tube, to a pressure transducer, and intraluminal pressure was recorded on an IBM PC-compatible computer. The outlet tubing was positioned at the same level as the inlet tubing. An upward deflection of at least 2 mmHg above baseline was defined as a motor response. Changes in intraluminal pressure were recorded via a digitizer on a computer using PowerLab R and the software Labchart7 R (ADInstruments Ltd). The duodenal motility was assessed in intervals of 10 min by planimetry to measure the total area under the pressure curve (area under the curve; AUC) during the sample period, as described previously (Nylander et al. 1989; Sommansson et al. 2013) . The values given are the mean ± SEM of three 10 min intervals (unless stated otherwise).
Measurement of luminal alkalinization
The rate of luminal alkalinization was determined by back titration of the perfusate to pH 4.90 with 10 mM HCl under continuous gassing (100% N 2 ) using pH-stat equipment (Autoburette ABU 901 and pH-stat controller PHM 290; Radiometer, Copenhagen, Denmark), as described previously (Nylander et al. 1989; Sommansson et al. 2013) . The pH electrode was routinely calibrated with standard buffers before the start of the titration. The amount of titrated HCl was considered equivalent to the duodenal mucosal HCO 3 − secretion. The rates of luminal alkalinization are expressed as micromoles of base secreted per centimetre of intestine per hour.
Measurement of epithelial fluid flux
The difference in the weight of the collection vials with and without perfusate was used to measure flow over a 10 min interval. The perfusate volumes were determined after correcting for density for each solution. The density of the isotonic saline was arbitrarily set to 1.0. The duodenum was perfused (ß0.4 ml min −1 ) with isotonic saline or other solutions, and the perfusate was collected every 10 min. The net fluid flux across the duodenal mucosa was determined by subtracting the perfusate volume per 10 min from the peristaltic pump volume per 10 min, and the result is expressed as millilitres of fluid per gram of wet tissue weight per hour. The peristaltic pump volume was determined from the average of two 10 min samples taken immediately after the termination of each experiment, as described previously (Nylander et al. 1989; Sommansson et al. 2013) .
Experimental protocol
In all of the experiments, the rates of duodenal mucosal paracellular permeability (in millilitres per minute per 100 grams), motility (AUC), bicarbonate secretion (in micromoles per centimetre per hour) and net fluid flux (in millilitres per gram per hour), as well as systemic arterial blood pressure (in millimetres of mercury) and body temperature (in degrees Celsius) were monitored continuously and recorded at 10 min intervals.
Control experiments were performed by measuring the parameters above with 120 min perfusions of the duodenal segment with isotonic saline (300 mosmol kg −1 ) at a rate of ß0.4 ml min −1 . In the animals administered luminal SCFAs, the experiments started with a duodenal perfusion of saline for 30 min to collect basal data. Next, the duodenal segment was perfused luminally with either 10 μM acetate or 10 μM propionate for 30 min followed by 500 μM for another 30 min. In another set of experiments, the protocol was the same except that the duodenal segment was perfused luminally with either 10 mM acetate or 10 μM propionate for 70 min.
For the animals administered SCFAs continuously by I.V. infusion, the experimental protocol was similar to the above except that the animal was infused I.V. with either acetate or propionate at 35 μmol kg
In animals administered GLP-2 by I.V. infusion, the experiment started with the perfusion of saline for 30 min to collect basal data. Then, GLP-2 was infused I.V. with 5, 25 or 75 nmol kg −1 h −1 during 30 min for each dosage. In the animals receiving a combination of propionate luminal perfusion and GLP-2 I.V. infusion, the experimental protocol was as above except that 10 mM propionate was perfused luminally at the same time as 25 nmol kg −1 h −1 GLP-2 was infused I.V. for 70 min. Immediately after finishing the experiment, the animal was killed with 1.0 ml bolus injection of 3 M KCl. Free fatty acid regulation in duodenal barrier function
Statistical analysis
Descriptive statistics are expressed as a mean ± SD, with the number of experiments given in parentheses. The statistical significance of the data was tested by repeated-measures ANOVA. To test the differences within a group, a one-factor repeated-measures ANOVA was used, followed by Tukey's post hoc test. Between the groups, a two-way repeated-measures ANOVA was used, followed by a Bonferroni post hoc test. Student's paired t test was used to test the differences within a group or between two groups. All the statistical analyses were performed on an IBM-compatible computer using the Prism software package 6.05 (GraphPad Software Inc., San Diego, CA, USA). A P value <0.05 was considered significant.
Results
In the control animals (N, number of animals, N = 7) perfused with isotonic saline, the duodenal motility, bicarbonate secretion and net fluid flux were stable at an average of 327 ± 131 AUC (10 min) −1 , 12.5 ± 4.1 μmol cm −1 h −1 and 0.82 ± 0.61 ml g −1 h −1 , respectively (Fig. 1B, C and D) . The mucosal paracellular permeability slightly decreased in a linear fashion from the start to the end of the experiments [from 0.28 ± 0.11 to 0.19 ± 0.065 ml min −1 (100 g) −1 ; P < 0.05; Fig. 1A] . A similar decline has been shown previously (Wan Saudi et al. 2015) . The mean arterial blood pressure and body temperature remained stable throughout the experiments in all of the groups (data not shown). Luminal short-chain fatty acids decreased the duodenal permeability (A), had no effect on motility (B), increased the duodenal bicarbonate secretion (C) and reduced the net duodenal fluid secretion (D). * P < 0.05 and * * P < 0.01, significant difference compared with the control group. # P < 0.05 and ## P < 0.01, significant difference compared with the baseline (0-30 min) in the same group.
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Effects of luminal acetate and propionate
The luminal concentrations of SCFAs are usually highest in the large intestine (ß100 mM; Cummings & Englyst, 1987; Mortensen & Clausen, 1996) . However, the proximal small intestine may reach concentrations as high as the millimolar range (Høverstad et al. 1984) . Interestingly, the role of SCFAs in the regulation of small intestinal barrier function is not well characterized.
In the present study, the luminal perfusion of either 10 μM acetate or 10 μM propionate (N = 6 of each group) for 30 min, followed by 500 μM for another 30 min, significantly reduced paracellular permeability (control; N = 7, P < 0.05; Fig. 1A) . Interestingly, although neither acetate nor propionate changed the motility AUC (Fig. 1B) , both SCFAs changed the pattern of the motility from a migrating motor complex (MMC) to a pattern similar to feeding motility. It was also shown that luminal acetate or propionate significantly increased bicarbonate secretion (P < 0.01; Fig. 1C ), as previously shown by Akiba et al. (2015) . However, we could not observe the dose-dependent secretory response they observed. Both acetate and propionate significantly reduced duodenal mucosal net fluid secretion (n, number of observations, N/n = 6/54, P < 0.05; Fig. 1D ).
Effects of I.V. acetate and propionate
The concentrations of acetate and propionate in the portal blood of rats are approximately 0.98 and 0.22 mM, respectively (Bugaut & Bentejac, 1993) . To elucidate whether changes in the plasma concentration of acetate and propionate (N = 5 of each group) influence duodenal barrier function and motility, SCFAs were administered by a continuous I.V. infusion at a dose of 35 μmol kg
for 70 min (control; N = 7). Both acetate and propionate significantly reduced the paracellular permeability (P < 0.05; Fig. 2A ). However, I.V. SCFA changed neither the duodenal motility (AUC; Fig. 2B ) nor the MMC pattern ( Fig. 3C; propionate not shown). The continuous I.V. infusion of both acetate and propionate induced decreases in duodenal bicarbonate secretion (P < 0.05; Fig. 2C ). No changes in fluid transport were observed (N/n = 5/45; Fig. 2D ).
Effects of I.V. GLP-2
It has been shown that both systemic and intraluminal administration of SCFAs increases the plasma concentrations of GLP-2 (Tappenden & McBurney, 1998; Akiba et al. 2015) . Thus, it is interesting to elucidate whether GLP-2 has the same effect relative to the actions of SCFAs. In the present study, the I.V. administration of continuous GLP-2 dosages of 5, 25 and 75 nmol kg
at 30 min intervals (n = 7) did not influence duodenal mucosal paracellular permeability (Fig. 4A ) and motility ( Figs 3D and 4B) . However, the highest dose of GLP-2 increased the rate of duodenal bicarbonate secretion (n = 7, P < 0.01; Fig. 4C ) and induced increases in fluid absorption (N/n = 6/54, P < 0.05; Fig. 4D ).
Effects of the co-administration of luminal propionate and I.V. GLP-2
Perfusion of the duodenal lumen with 10 mM acetate (not shown) and 10 mM propionate for 70 min did not affect the mucosal paracellular permeability or the motility AUC ( Fig. 5A and B) . However, it significantly increased the duodenal bicarbonate secretion (N = 6, P < 0.01; Fig. 5C ) and net fluid secretion (N/n = 6/54, P < 0.05; Fig. 5D ). This bicarbonate secretory increase was not significantly different from the rates induced by 500 μM acetate or propionate (Fig. 1C) . Interestingly, the co-administration with 25 nmol kg −1 h −1 GLP-2 I.V. infusion abolished the effects of the luminal SCFAs (10 mM) on the duodenal bicarbonate secretion (Fig. 5C ) and significantly reduced the duodenal motility (Figs 3E and 5B; N = 6; P < 0.01). In contrast, the luminal SCFAs changed the fasting motility pattern into a feeding motility pattern with the GLP-2 I.V. infusion (Fig. 3E) . No changes were observed in either the duodenal mucosal paracellular permeability or net fluid flux ( Fig. 5A and D) .
Discussion
The integrity of the duodenal mucosal barrier is dependent on different mechanisms, such as paracellular permeability, bicarbonate transport and fluid secretion (Sjöblom, 2011; Sedin et al. 2012; Sommansson et al. 2013) . In recent years, it has become clearer that the presence of intraluminal nutrients plays a more important role in regulating mucosal barrier function than was previously hypothesized . In the present study, we show that the luminal perfusion of the short-chain fatty acids acetate or propionate significantly decreased the duodenal paracellular permeability and increased the rate of duodenal mucosal bicarbonate secretion in anaesthetized rats. However, increasing the systemic concentration of SCFAs by I.V. infusion of acetate or propionate induced the same effects as luminal stimulation on paracellular permeability but significantly decreased the bicarbonate transport.
The role of intestinal SCFAs in regulating mucosal barrier function and chemosensing has been studied mainly in the colon, where bacterial fermentation of undigested fibres and carbohydrates produces fatty acids at concentrations in the 100 mM range (Cummings & Englyst, 1987; Mortensen & Clausen, 1996; Topping & Clifton, 2001 ). Interestingly, Akiba et al. (2015) showed that SCFAs induce important barrier protective mechanisms in the proximal small intestine. In a similar experimental model to that of the present study, it was shown that luminal perfusion of acetate increased duodenal bicarbonate secretion in a dose-dependent manner via dual mechanisms involving the activation of both FFA2 receptors expressed on enterochromaffin cells and FFA3 receptors expressed on endocrine L cells. Although we did not observe a dose-dependent increase in the response to luminal SCFAs, we found that fatty acids induced an increase in bicarbonate secretion. An interesting observation of the present study was that the I.V. administration of acetate or propionate significantly reduced the rate of duodenal bicarbonate transport. The reason for these differences is not clear. It is possible that FFA receptor activation within the enteric nervous system induced the opposite effects compared with activation of receptors expressed by endocrine cells (Kimura et al. 2011; Nøhr et al. 2013; López Soto et al. 2014) . Supporting this notion is that apical FFA3 receptors expressed by L cells increase duodenal bicarbonate secretion via release of GLP-1/GLP-2 (Tolhurst et al. 2012; Akiba et al. 2015) , and activation of neural FFA3 receptors suppresses nicotinic acetylcholine receptor-stimulated Cl − secretion in rat proximal colon (Kaji et al. 2016) . Whether the latter also occurs in the duodenum needs to be investigated further, but it seems likely that SCFAs administered I.V. influence enteric neural circuitry to a greater extent than luminal SCFAs. If FFA3 receptors supress cholinergic (nicotinic) neural activity in the duodenum it is likely that I.V. SCFAs mediate its secretory inhibition by this pathway, because it is evident from other studies that nicotinic acetylcholine-blocking agents (such as hexamethonium or mecamylamine) inhibit both basal and stimulated Luminal short-chain fatty acid I.V. infusion decreased duodenal permeability (A) and bicarbonate secretion (C), but had no effect on the duodenal motility (B) or net fluid secretion (D). * P < 0.05, significant difference compared with the control group. # P < 0.05 and ## P < 0.01, significant difference compared with the baseline (0-30 min) in the same group. Representative experiments are shown. All of the rats were pretreated with 10 mg kg −1 parecoxib I.V., ß60 min before the experiment started, in order to reverse the surgery-induced paralytic ileus. A, migrating motor complex (MMC)-like motility, showing cyclic periods of quiescence followed by a period of intense contractions in a control rat. B, perfusion of the duodenal lumen with acetate changed motility from an MMC-like pattern to a pattern with continuous irregular contractions (similar to fed state motility), whereas neither I.V. acetate (C) nor I.V. glucagon-like peptide-2 (GLP-2; D) changed the MMC pattern. E, co-administration of GLP-2 (I.V. infusion) and propionate (luminal) significantly reduced the motility (area under the curve) and changed the motility from MMC to a fed state pattern.
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duodenal bicarbonate secretion (Sjöblom & Flemström, 2003; Sommansson et al. 2014a) . Additionally, it has been shown that activation of the FFA receptors induces inhibitory effects via sympathetic neurons (Won et al. 2013) . It is also reasonable to question whether the luminal concentrations of SCFAs used in the present study were within the physiological range, because the major source of SCFAs is from the caecum and colon. Høverstad et al. (1984) showed that SCFAs are present in the proximal small intestine of healthy humans in the millimolar range, and it has been suggested that the major source of foregut fatty acids originates from the oral commensal bacteria. In addition, substantial amounts of SCFAs enter the gastrointestinal tract via food and nutrition supplementation. FFA2 and FFA3 receptors are specific for SCFAs and are expressed in the caecum and the proximal colon. They are also highly expressed in the proximal small intestine Kaji et al. 2015) . Thus, our study confirmed the stimulatory effects of duodenal bicarbonate secretion by luminal SCFAs in a continuous perfusion of anaesthetized rats in vivo. Kaji et al. (2015) showed that luminal SCFAs stimulate duodenal bicarbonate secretion by activating SMCT1 and the pH-dependent MCTs. It is hypothesized that luminal SCFAs are electrogenically cotransported with Na + via the apical SMCT1 and exit an enterocyte at the basolateral membrane in exchange for HCO 3 − by the MCT. The increased intracellular HCO 3 − exits the duodenocytes into the lumen via the Cl − -HCO 3 − exchanger . Our finding that luminal SCFAs increase fluid absorption, as the activation of apical SMCT1 provides a driving force for fluid absorption, supports this mechanism. In addition, an increased SCFA plasma concentration (by the I.V. administration of SCFAs) might induce SCFA uptake at the basolateral surface by the MCT and, as a Glucagon-like peptide-2 had no effect on duodenal permeability (A) or motility (B), but increased the duodenal bicarbonate secretion (C) and stimulated the duodenal net fluid absorption (D). * * P < 0.01, significant difference compared with the control group. # P < 0.05 and ## P < 0.01, significant difference compared with the baseline (0-30 min) in the same group.
result, reduce the intracellular bicarbonate concentration. This mechanism may be an additional alternative to the above-suggested possibilities and may explain how I.V. acetate and propionate reduce bicarbonate secretion but have no effect on fluid transport. Interestingly, we show that I.V. GLP-2 mediates duodenal bicarbonate secretion, which is supported by the study of Wang et al. (2011) using a similar experimental set-up. Glucagon-like peptide-2 also stimulates fluid absorption, possibly by a mechanism downstream of FFA3 receptor activation on L cells Kaji et al. 2015) , thus increasing Na + absorption and cotransport of water via SMCT1. The combination of propionate and GLP-2 was hypothesized to have synergistic effects. However, no changes in the rate of duodenal bicarbonate secretion or net fluid flux were observed, suggesting an interfering signalling mechanism. In addition, the duodenal bicarbonate secretory response to luminal acetate or propionate at a concentration of 10 mM was not different from that of 500 μM, suggesting that a maximal effect is already reached in the millimolar range. This concentration of acetate is close to the level generally found in duodenal juices (ß400 μM; Høverstad et al. 1984) . 
infusion reduced duodenal motor activity
A, the propionate alone and propionate co-administration with GLP-2 had no effect on duodenal permeability. B, the combination of propionate and GLP-2 reduced duodenal motor activity. Luminal propionate 10 mM increased the duodenal bicarbonate secretion (C) and net fluid secretion (D). * * P < 0.01, significant difference compared with the control group. # P < 0.05 and ## P < 0.01, significant difference compared with the baseline (0-30 min) in the same group.
An interesting observation is that the administration of SCFAs as either a luminal perfusion or an I.V. infusion decreased the duodenal mucosal paracellular permeability. To the best of our knowledge, this is the first time it has been shown that the acute (<30 min) effects of administration of SCFAs reduce duodenal permeability in rats in vivo. This finding seems consistent with the immediate (ß10 min) effects of SCFAs observed in vitro in caecal tissue mounted in Ussing chambers (Suzuki et al. 2008) . As the effects of administered SFCAs occur within minutes, it seems unlikely that the changes in paracellular permeability are caused by changes in the expression of tight junctional proteins. To us, it seems more likely that the cause of the changed permeability is inhibition of circumferential contraction and tension of the actin filaments regulated by the myosin light chain, resulting in less opening of the paracellular pathways, as was first suggested by Turner et al. (1997) . These changes are likely to be induced by an altered enteric neural activity. Short-chain fatty acid activation of FFA2 receptors might decreases mucosal permeability mainly via mechanisms involving 5-HT 3 and 5-HT 4 receptor-mediated pathways. It was shown by that the 5-HT 4 antagonist SB203186 reduces luminal hypotonicity-induced increases in permeability, suggesting that 5-HT binding to the 5-HT 4 receptor subtype normally causes a permeability increase. In addition, the same is found with the 5-HT 3 antagonists ondansetron and granisetrone, suggesting that serotonin binding to 5-HT 3 receptors also causes permeability increases. The effects of SCFAs in reducing paracellular permeability would therefore suggest that SCFAs induce a reduced enteric serotonergic activity and less activation of 5-HT 3 and/or 5-HT 4 receptors. In the present study, we also found that I.V. administration of GLP-2 did not induce any effects on the duodenal mucosal paracellular permeability.
Previously, luminal SCFAs have been shown to stimulate colonic motor activity (Yajima, 1985; Mitsui et al. 2005) . Our study shows that SCFAs in the duodenal segment have no effects on the total duodenal motility (measured as the total AUC), an observation supported by observations in humans (Masliah et al. 1992) . However, an interesting finding was that the motility pattern during luminal perfusion with acetate and propionate changed from a pattern normally observed during the fasting state, called the MMC, to a pattern observed during a fed state. The MMC is a cyclic and distinct pattern characterized by a period of quiescence followed by a period of intense contractions, whereas in the fed state motility has continuous irregular contractions. Likewise, it was also shown previously that perfusing the ileal segment, but not the I.V. administration of SCFAs, changed the gastric and duodenal motility patterns (Cuche & Malbert, 1999; Cuche et al. 2000) . The mechanism responsible for the shift in motility pattern needs to be investigated further.
Surprisingly, the combination of propionate and GLP-2 induced a reduction in duodenal motor activity. The studies by Tolhurst et al. (2012) and Psichas et al. (2015) have shown that luminal SCFAs stimulate GLP-1 release via FFA2 activation in colonic cells. In comparison, Bozkurt et al. (2002) demonstrated that co-stimulation with GLP-1 and GLP-2 reduced small intestinal spiking activity in the fasted rats. Therefore, it is plausible that luminal propionate induces increases in the GLP-1 plasma concentration and, together with GLP-2 I.V. administration, causes an inhibitory effect on duodenal motility.
In conclusion, luminal SCFAs significantly reduced the duodenal mucosal paracellular permeability, decreased the transepithelial net fluid secretion and induced opposite effects on luminal alkalinization after luminal and I.V. administration. This study proposes that SCFAs have a role in the regulation of duodenal barrier function and that a dysregulation in this system might contribute to the pathology observed in patients with functional dyspepsia or inflammatory bowel syndrome.
